Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575185 · ClinicalTrials.gov registry record · Phase 1
Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00575185 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 23 participants.
The verdict
NCT00575185, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis documented to be caused by primary EBV infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical diagnosis of primary infectious mononucleosis will be screened and those with laboratory-confirmed primary EBV infection will be enrolled.
Interventions
- DRUG placebo
- DRUG Valomaciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575185
The ClinicalTrials.gov registry entry for NCT00575185 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00575185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00575185 about?
NCT00575185 is a clinical study titled "Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection". This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis documented to be caused by primary EBV infection. Otherwise healthy subj...
What is the current status of trial NCT00575185?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-11. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00575185?
The interventions under investigation include: placebo (DRUG), Valomaciclovir (DRUG).
Who is sponsoring clinical trial NCT00575185?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.